Table 2 Response rates (IRC assessment)

From: ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

 

Evaluable population ( N)

Intent to treat population ( N)

Overall

58 (91%)

64 (100%)

Not assessable

 

6 (9%)

Complete response (CR)

1 (2%)

1 (2%)

Partial response (PR)

19 (33%)

19 (30%)

Stable disease (SD)

29 (50%)

29 (45 %)

Progressive disease (PD)

9 (15%)

9 (14 %)

ORR

20 (34%)

20 (31%)

95% CI

(22–47)

(20–43)

Back to article page